Page 3 - Leonard Zon News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Leonard zon. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Leonard Zon Today - Breaking & Trending Today

Fate Therapeutics (NASDAQ:FATE) Price Target Cut to $5.00 by Analysts at Cantor Fitzgerald

Fate Therapeutics (NASDAQ:FATE – Get Rating) had its price target trimmed by Cantor Fitzgerald from $8.00 to $5.00 in a research report report published on Thursday, The Fly reports. Several other brokerages have also issued reports on FATE. Morgan Stanley cut their price target on Fate Therapeutics from $35.00 to $8.00 and set an equal […] ....

Philip Beachy , Leonard Zon , Rudolf Jaenisch , David Scadden , Alexander Rives , Scott Wolchko , Michael Rudnicki , Morgan Stanley , Nisa Investment Advisors , Coppell Advisory Solutions Corp , Ci Investments Inc , Fate Therapeutics Inc , Cantor Fitzgerald , Managers Group , Redmile Group Llc , Fate Therapeutics , Get Rating , Director Redmile Group , Investment Advisors , Coppell Advisory Solutions , Sheng Ding , Fate Therapeutics Daily , Nasdaq Fate , Lower Price Target ,

Comparing Surrozen (NASDAQ:SRZN) & Fate Therapeutics (NASDAQ:FATE)

Surrozen (NASDAQ:SRZN – Get Rating) and Fate Therapeutics (NASDAQ:FATE – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, valuation, profitability, analyst recommendations, earnings and dividends. Profitability This table compares Surrozen and Fate Therapeutics’ net margins, […] ....

San Diego , United States , South San Francisco , Philip Beachy , Johnd Mendlein , Rudolf Jaenisch , Leonard Zon , Alexander Rives , David Scadden , Scott Wolchko , Michael Rudnicki , Fate Therapeutics Inc , Surrozen Inc , Get Rating , Fate Therapeutics , Fate Therapeutic , Given Fate Therapeutic , Sheng Ding , Surrozen Daily , Nasdaq Srzn , Stock Comparison , Stock Analysis ,

Analysts Set Expectations for Fate Therapeutics, Inc.'s Q4 2024 Earnings (NASDAQ:FATE)

Fate Therapeutics, Inc. (NASDAQ:FATE – Get Rating) – Research analysts at SVB Leerink issued their Q4 2024 earnings per share estimates for Fate Therapeutics in a research report issued on Thursday, May 4th. SVB Leerink analyst D. Graybosch anticipates that the biopharmaceutical company will post earnings of ($0.45) per share for the quarter. SVB Leerink […] ....

Philip Beachy , Alexander Rives , Scott Wolchko , Michael Rudnicki , Rudolf Jaenisch , David Scadden , Leonard Zon , Fate Therapeutics Inc , Redmile Group Llc , Fate Therapeutics Company Profile , Cantor Fitzgerald , Financial Services Group Inc , Royal Bank , Wells Fargo Company , Fate Therapeutics , Get Rating , Fate Therapeutic , Truist Financial , Therapeutics Trading Down , Pension Plan Investment Board , Services Group , Two Sigma Advisers , Sigma Advisers , Director Redmile Group , Sheng Ding , Fate Therapeutics Daily ,

Fate Therapeutics (NASDAQ:FATE) Releases Earnings Results, Beats Estimates By $0.36 EPS

Fate Therapeutics (NASDAQ:FATE – Get Rating) announced its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.36, Briefing.com reports. Fate Therapeutics had a negative return on equity of 50.86% and a negative net margin of 292.55%. The firm had […] ....

United States , Alexander Rives , Rudolf Jaenisch , Philip Beachy , Stifel Nicolaus , Leonard Zon , David Scadden , Scott Wolchko , Michael Rudnicki , Vanguard Group Inc , Fate Therapeutics Inc , Pricet Rowe Associates Inc , Fate Therapeutics Company Profile , Redmile Group Llc , Blackrock Inc , Wells Fargo Company , Fate Therapeutics , Get Rating , Therapeutics Stock Down , Director Redmile Group , Street Corp , Capital World Investors , World Investors , Sheng Ding , Fate Therapeutics Daily , Nasdaq Fate ,

Gamble Jones Investment Counsel Decreases Stock Position in NextEra Energy, Inc. (NYSE:NEE)

Fate Therapeutics (NASDAQ:FATE – Get Rating) released its earnings results on Wednesday. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.36, Briefing.com reports. The firm had revenue of $58.98 million during the quarter, compared to the consensus estimate of $33.53 million. Fate Therapeutics had a […] ....

United States , David Scadden , Michael Rudnicki , Scott Wolchko , Philip Beachy , Leonard Zon , Alexander Rives , Rudolf Jaenisch , Envestnet Asset Management Inc , Financial Services Group Inc , Securities Exchange Commission , Raymond James Associates , Ef Hutton Acquisition Co , Redmile Group Llc , Advisor Group , Fate Therapeutics Inc , Hightower Advisors , Fate Therapeutics , Get Rating , Director Redmile Group , Exchange Commission , Asset Management , Tower Advisors , Services Group , Truist Financial , Sheng Ding ,